Advertisement
Screener

Exelixis Inc (EXEL) Revenues

2.8 / 5 stars · 68/120 Roast Me

Exelixis Inc Revenues

Exelixis Inc (EXEL) reported Revenues of $231.09 million for the 3-month period ending 2020-10-02, per its 10-Q filed 2020-11-05.

Discontinued › Income Statement › Revenue

us-gaap:Revenues · last filed 2020-11-05

  • Exelixis Inc revenues for the quarter ending 2020-10-02 was $231.09M, a 14.95% decline year-over-year.
  • Exelixis Inc revenues for the quarter ending 2020-07-03 was $259.48M, a 7.99% increase year-over-year.
  • Exelixis Inc revenues for the quarter ending 2020-04-03 was $226.91M, a 5.30% increase year-over-year.
  • Exelixis Inc revenues for the quarter ending 2019-09-27 was $271.70M.
  • Exelixis Inc revenues for fiscal 2017 was $452.48M, a 136.34% increase from fiscal 2016.
  • Exelixis Inc revenues for fiscal 2016 was $191.45M.
  • Exelixis Inc revenues for fiscal 2016 was $191.45M, a 415.05% increase from fiscal 2016.
  • Exelixis Inc revenues for fiscal 2016 was $37.17M.
Period endRevenues 3 monthRevenues 3 month as first filedRevenues 6 monthRevenues 9 monthRevenues 12 month
2020-10-02$231.09M
10-Q · filed 2020-11-05
$490.57M
derived: sum of 2 quarters · filed 2020-11-05
$717.49M
10-Q · filed 2020-11-05
2020-07-03$259.48M
10-Q · filed 2020-08-06
$486.39M
10-Q · filed 2020-08-06
2020-04-03$226.91M
10-Q · filed 2020-05-05
2019-09-27$271.70M
10-Q · filed 2020-11-05
$511.98M
derived: sum of 2 quarters · filed 2020-11-05
$727.47M
10-Q · filed 2020-11-05
2019-06-28$240.28M
10-Q · filed 2020-08-06
$455.76M
10-Q · filed 2020-08-06
2019-03-29$215.49M
10-Q · filed 2020-05-05
2018-06-29$186.11M
10-Q · filed 2018-08-01
$399.83M
10-Q · filed 2018-08-01
$519.88M
derived: sum of 3 quarters · filed 2018-08-01
$672.39M
derived: sum of 4 quarters · filed 2018-08-01
2018-03-30$213.70M
10-Q · filed 2018-08-01
$212.35M
10-Q · filed 2018-05-02
$333.77M
derived: sum of 2 quarters · filed 2018-08-01
$486.28M
derived: sum of 3 quarters · filed 2018-08-01
2017-12-29$120.07M
10-K · filed 2018-02-26
$272.58M
derived: sum of 2 quarters · filed 2018-02-26
$452.48M
10-K · filed 2018-02-26
2017-09-30$152.51M
10-Q · filed 2017-11-01
$332.40M
10-Q · filed 2017-11-01
2017-09-29$152.51M
10-K · filed 2018-02-26
$251.52M
derived: sum of 2 quarters · filed 2018-08-01
$332.40M
derived: sum of 3 quarters · filed 2018-08-01
$409.99M
derived: sum of 4 quarters · filed 2018-08-01
2017-06-30$99.01M
10-Q · filed 2018-08-01
$179.90M
10-Q · filed 2017-08-02
$257.48M
derived: sum of 3 quarters · filed 2018-08-01
2017-03-31$80.89M
10-Q · filed 2017-05-01
$158.47M
derived: sum of 2 quarters · filed 2018-05-02
2016-12-31$77.58M
10-K · filed 2017-02-27
$191.45M
10-K · filed 2017-02-27
2016-12-30$77.58M
10-K · filed 2018-02-26
$139.78M
derived: sum of 2 quarters · filed 2018-02-26
$176.03M
derived: sum of 3 quarters · filed 2018-02-26
$191.45M
10-K · filed 2018-02-26
2016-09-30$62.19M
10-K · filed 2018-02-26
$98.45M
derived: sum of 2 quarters · filed 2018-02-26
$113.87M
10-Q · filed 2017-11-01
2016-07-01$36.25M
10-K · filed 2018-02-26
2016-06-30$36.25M
10-Q · filed 2017-08-02
$51.68M
10-Q · filed 2017-08-02
2016-04-01$15.43M
10-K · filed 2018-02-26
2016-03-31$15.43M
10-Q · filed 2017-05-01
$25.36M
derived: sum of 2 quarters · filed 2017-05-01
$35.22M
derived: sum of 3 quarters · filed 2017-05-01
$43.21M
derived: sum of 4 quarters · filed 2017-05-01
2016-01-01$37.17M
10-K · filed 2018-02-26
2015-12-31$9.94M
10-K · filed 2017-02-27
$19.79M
derived: sum of 2 quarters · filed 2017-02-27
$27.78M
derived: sum of 3 quarters · filed 2017-02-27
$37.17M
10-K · filed 2017-02-27
2015-09-30$9.85M
10-K · filed 2017-02-27
$17.85M
derived: sum of 2 quarters · filed 2017-02-27
$27.23M
10-Q · filed 2016-11-03
$34.59M
derived: sum of 4 quarters · filed 2017-02-27
2015-06-30$7.99M
10-K · filed 2017-02-27
$17.38M
10-Q · filed 2016-08-03
$24.73M
derived: sum of 3 quarters · filed 2017-02-27
$31.02M
derived: sum of 4 quarters · filed 2017-02-27
2015-03-31$9.39M
10-K · filed 2017-02-27
$16.74M
derived: sum of 2 quarters · filed 2017-02-27
$23.03M
derived: sum of 3 quarters · filed 2017-02-27
$29.59M
derived: sum of 4 quarters · filed 2017-02-27
2014-12-31$7.35M
10-K · filed 2016-02-29
$13.64M
derived: sum of 2 quarters · filed 2016-02-29
$20.21M
derived: sum of 3 quarters · filed 2016-02-29
$25.11M
10-K · filed 2017-02-27
2014-09-30$6.29M
10-K · filed 2016-02-29
$12.85M
derived: sum of 2 quarters · filed 2016-02-29
$17.76M
10-Q · filed 2015-11-10
$22.11M
derived: sum of 4 quarters · filed 2016-02-29
2014-06-30$6.56M
10-K · filed 2016-02-29
$11.47M
derived: sum of 2 quarters · filed 2016-02-29
$15.81M
derived: sum of 3 quarters · filed 2016-02-29
$21.28M
derived: sum of 4 quarters · filed 2016-02-29
2014-03-31$4.91M
10-K · filed 2016-02-29
$9.25M
derived: sum of 2 quarters · filed 2016-02-29
$14.72M
derived: sum of 3 quarters · filed 2016-02-29
$26.57M
derived: sum of 4 quarters · filed 2016-02-29
2013-12-31$4.35M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29
$9.81M
derived: sum of 2 quarters · filed 2016-02-29
$21.67M
derived: sum of 3 quarters · filed 2016-02-29
$31.34M
10-K · filed 2016-02-29
2013-09-30$5.47M
10-Q · filed 2013-10-30
$17.32M
derived: sum of 2 quarters · filed 2013-10-30
$26.99M
10-Q · filed 2013-10-30
$34.80M
derived: sum of 4 quarters · filed 2015-03-02
2013-06-30$11.86M
10-Q · filed 2013-08-06
$21.52M
10-Q · filed 2013-08-06
$29.34M
derived: sum of 3 quarters · filed 2015-03-02
$42.65M
derived: sum of 4 quarters · filed 2015-03-02
2013-03-31$9.67M
10-Q · filed 2014-05-01
$17.48M
derived: sum of 2 quarters · filed 2015-03-02
$30.80M
derived: sum of 3 quarters · filed 2015-03-02
$38.61M
derived: sum of 4 quarters · filed 2015-03-02
2012-12-31$7.81M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02
$21.13M
derived: sum of 2 quarters · filed 2015-03-02
$28.94M
derived: sum of 3 quarters · filed 2015-03-02
$47.45M
10-K · filed 2015-03-02
2012-09-30$13.31M
10-Q · filed 2013-10-30
$21.13M
derived: sum of 2 quarters · filed 2013-10-30
$39.64M
10-Q · filed 2013-10-30
$132.94M
derived: sum of 4 quarters · filed 2014-02-20
2012-06-30$7.81M
10-Q · filed 2013-08-06
$26.32M
10-Q · filed 2013-08-06
$119.63M
derived: sum of 3 quarters · filed 2014-02-20
$247.90M
derived: sum of 4 quarters · filed 2014-02-20
2012-03-31$18.51M
10-Q · filed 2013-05-07
$111.82M
derived: sum of 2 quarters · filed 2014-02-20
$240.09M
derived: sum of 3 quarters · filed 2014-02-20
$272.25M
derived: sum of 4 quarters · filed 2014-02-20
2011-12-31$93.31M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20
$221.58M
derived: sum of 2 quarters · filed 2014-02-20
$253.74M
derived: sum of 3 quarters · filed 2014-02-20
$289.64M
10-K · filed 2014-02-20
2011-09-30$128.27M
10-Q · filed 2012-11-07
$160.43M
derived: sum of 2 quarters · filed 2012-11-07
$196.33M
10-Q · filed 2012-11-07
$237.10M
derived: sum of 4 quarters · filed 2013-02-21
2011-06-30$32.16M
10-Q · filed 2012-08-02
$68.06M
10-Q · filed 2012-08-02
$108.83M
derived: sum of 3 quarters · filed 2013-02-21
$163.31M
derived: sum of 4 quarters · filed 2013-02-21
2011-03-31$35.89M
10-Q · filed 2012-05-03
$76.67M
derived: sum of 2 quarters · filed 2013-02-21
$131.14M
derived: sum of 3 quarters · filed 2013-02-21
$178.74M
derived: sum of 4 quarters · filed 2013-02-21
2010-12-31$40.78M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21
$95.25M
derived: sum of 2 quarters · filed 2013-02-21
$142.85M
derived: sum of 3 quarters · filed 2013-02-21
$185.04M
10-K · filed 2013-02-21
2010-09-30$54.47M
10-Q · filed 2011-10-27
$102.07M
derived: sum of 2 quarters · filed 2011-10-27
$144.27M
10-Q · filed 2011-10-27
2010-06-30$47.60M
10-Q · filed 2011-08-04
$89.80M
10-Q · filed 2011-08-04
2009-12-31$151.76M
10-K · filed 2012-02-22

Similar stocks

Stock NameCountryMarket CapPE Ratio
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Twist Bioscience Corp (TWST)United States$11.540B-47.21
BIO-TECHNE Corp (TECH)United States$11.379B74.68
REPLIGEN CORP (RGEN)United States$10.755B185.31
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
Immunovant, Inc. (IMVT)United States$7.028B-14.78